Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

Premium Quality Power IPO Day 2 Highlights: The subscription period for the Quality Power IPO is scheduled from Friday, February 14, to Tuesday, February 18. Quality Power IPO Day 2 Highlights ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

A man has been arrested on suspicion of attempted murder after a van struck two people in Poulton Le-Fylde just after midnight. Police received a report at 12.50am today, Sunday, that a Ford ...

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth. Click here to read why ALNY is a Buy.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...

Alnylam's lead candidate for ATTR-CM, Amvuttra (vutrisiran), has shown promising results in the HELIOS-B clinical trial. The top-line data demonstrated a significant reduction in mortality ...

Management has forecast top sales of $5 billion for brensocatib in NCFB alone. 4. Alnylam’s Amvuttra/vutrisiran (ATTR-CM) Alnylam’s key pipeline drug, Amvuttra (vutrisiran) has an FDA decision date of ...